"Genetic Material Once Considered Junk Actually Could Hold Key To Cancer Drug Response"
Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy, possibly offering better insight than the type of material that is being sequenced, according to a study by Mount Sinai researchers published in Cell Reports. "Our conclusions make the case that non-coding RNA in tumors, particularly repetitive elements, is under-quantified," said the study's senior author, Benjamin Greenbaum, PhD, assistant professor of oncological sciences, pathology, medicine, hematology and medical oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "We feel that critical findings will arise from analysis of the full breadth of a tumor's non-coding RNA interplay with the immune system."
- Benjamin D. Greenbaum, PhD, Assistant Professor, Medicine, Hematology and Medical Oncology, Pathology, Oncological Sciences, Icahn School of Medicine at Mount Sinai
Additional coverage: